Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016
Published Aug 10, 2016
42 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016, provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- Identify the use of drugs for target identification

  
Source:
Document ID
GMDHC0452TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview61
Therapeutics Development73
  Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Stage of Development71
  Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Therapy Area81
  Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Indication91
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Companies122
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Companies Involved in Therapeutics Development206
  Crescendo Biologics Limited201
  Exicure, Inc.211
  Novartis AG221
  Teva Pharmaceutical Industries Ltd.231
  UCB S.A.241
  Vipergen ApS251
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Drug Profiles2610
  Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders Drug Profile261
  bimekizumab Drug Profile271
  CB-001 Drug Profile281
  E-34935 Drug Profile291
  E-35018 Drug Profile301
  E-35762 Drug Profile311
  E-36041 Drug Profile322
  Recombinant Protein to Inhibit IL-17A for Psoriasis Drug Profile341
  Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases Drug Profile351
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Dormant Projects361
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Featured News &Press Releases374
  Jun 10, 2016: UCB s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis371
  Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016)381
  Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists381
  Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting391
  Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies391
  Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting401
Appendix412
  Methodology411
  Coverage411
  Secondary Research411
  Primary Research411
  Expert Panel Validation411
  Contact Us411
  Disclaimer421

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-17-Receptor-A-CDw217-or-CD217-or-IL17RA-Pipeline-Review-H2-2016-2088-16374>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-17-Receptor-A-CDw217-or-CD217-or-IL17RA-Pipeline-Review-H2-2016-2088-16374>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.